The association between the expression of Survivin mRNA and ovarian cancer: a meta-analysis_Chinese Journal of Evidence-Based Medicine

Authors：

XU Yingyi , ZHANG Yaya , LIN Zhicai ,  CHEN Yuqiang

Department of Oncology, Chenggong Hospital Affiliated to Xiamen University, No.174 Hospital of PLA, Xiamen, 361003, P.R.China;

Corresponding author：

CHEN Yuqiang, Email: chenyq707@163.com

Keywords：

Survivin; Ovarian neoplasms; Meta-analysis; Systematic review; Case-control study

DOI：

10.7507/1672-2531.201611081

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the relationship between the expression of Survivin mRNA and ovarian cancer. Methods PubMed, The Cochrane Library (Issue 11, 2016), CBM, CNKI, VIP and WanFang Data databases were searched to identify case-control studies concerning the association between the expression of Survivin mRNA and ovarian cancer up to November 2016. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Then, meta-analysis was performed using RevMan 5.2 software. Results A total of 10 studies were included. The positive of Survivin mRNA in ovarian cancer group was significantly higher than that in control group (OR=24.63, 95% CI 13.44 to 45.15,P<0.000 01). The positive of Survivin in low differentiated group was significantly higher than that in high differentiation group (OR=3.69, 95% CI 2.29 to 5.93,P<0.000 01). The positive of Survivin in clinical stage of Ⅲ-Ⅳ was significantly higher than that in clinical stage of Ⅰ-Ⅱ (OR=4.76, 95% CI 2.99 to 7.57,P<0.000 01), respectively. However, the expression of Survivin mRNA was not associated with lymph node metastasis, ascites and histological type. Conclusion The current evidence indicates that the expression of Survivin mRNA is significantly correlated with ovarian cancer and its clinicopathologic features. Due to the limited quantity and quality of includes studies, the above conclusions are needed to be verified by more high quality studies.

Citation： XU Yingyi, ZHANG Yaya, LIN Zhicai, CHEN Yuqiang. The association between the expression of Survivin mRNA and ovarian cancer: a meta-analysis. Chinese Journal of Evidence-Based Medicine, 2017, 17(3): 320-326. doi: 10.7507/1672-2531.201611081 Copy

1.	Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55(2): 74-108.
2.	Basu P, De P, Mandal S, et al. Study of pattern of care of ovarian cancer patients in specialized cancer institute in Kolkata, Eastern India. Indian J Cancer, 2009, 46(1): 28-33.
3.	Modepalli N, Venugopal SB. Clinicopathological study of surface epithelial tumours of the ovary: an isntitutional study. J Clin Diagn Res, 2016, 10(10): EC01-EC04.
4.	李克红, 张若曦, 张英杰, 等. 凋亡抑制基因 Survivin 在卵巢癌组织中的表达及其临床意义. 中国实用医刊, 2012, 39(8): 4-6.
5.	史惠蓉, 兰莉, 乔玉环, 等. 卵巢癌组织中 Survivin 和 PCNA 的表达. 郑州大学学报(医学版), 2004, 39(4): 552-554.
6.	宋和存, 向征, 李慧. Survivin Ki67 在卵巢原发癌与转移癌中的表达及其临床意义. 中国实用妇科与产科杂志, 2006, 22(3): 201-203.
7.	王言奎, 杨锦芝, 罗兵, 等. 上皮性卵巢癌中 Survivin 的表达及意义. 中国妇产科临床杂志, 2003, 4(5): 368-372.
8.	杨锦芝, 赵冬梅. 凋亡抑制基因 Survivin 在上皮性卵巢癌中的表达及其意义. 滨州医学院学报, 2003, 26(4): 243-244.
9.	Li GZ, Pei SL, Hong LM, et al. Survivin expression in ovarian cancer. Exp Oncol, 2007, 29(2): 121-125.
10.	张淑兰, 赵长清, 林蓓, 等. 凋亡抑制基因 survivin 在卵巢上皮性癌组织中的表达及其与 bcl-2、bax 蛋白表达的关系. 中华妇产科杂志, 2003, 38(4): 203-206.
11.	张树荣, 杨淑莉, 李荷莲. 卵巢癌组织中 MDR1、Survivin、TopoⅡβ 的表达及临床意义. 中国妇幼健康研究, 2006, 17(6): 464-466.
12.	张意茗, 张向宁. XIAP、survivin、LPA 及 CA125 在上皮性卵巢癌中的表达. 山东大学学报(医学版), 2007, 45(3): 317-321.
13.	赵杨, 张颐, 温放. 凋亡抑制蛋白和耐药因子在卵巢癌中的表达及与化疗的关系. 解剖科学进展, 2007, 13(2): 111-114, 118.
14.	Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the qualityof nonrandomized studies in meta-analysis. Available at: .
15.	许英艺, 张雅雅, 卢伟锋, 等. 骨桥蛋白表达与中国人肝癌及临床病理特征关系的 Meta 分析. 中国循证医学杂志, 14(12): 1418-1423.
16.	Ambrosini G, Adida C, Sirugo G, et al. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem, 1998, 273(18): 11177-11182.
17.	Shin S, Sung BJ, Cho YS, et al. An anti-apoptotic protein human a survivin is a direct inhibitor of caspase-3 and -7. Biochemistry, 2001, 40(4): 1117-1123.
18.	Grossman D, McNiff JM, Li F, et al. Expression and targeting of the apoptosis inhibtitor, Survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line. Lab Invest, 1999, 79(9): 1121-1126.
19.	Grossman D, McNiff JM, Li F, et al. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol, 1999, 113(6): 1076-1081.
20.	Nasu S, Yangihashi A, Izawa A, et al. Survivin mRNA expression in patients with breast cancer. Anticancer Res, 2002, 22(3): 1839-1843.
21.	Smith SD, Wheeler MA, Plescia J, et al. Urine detection of survivin and diagnosis of bladder cancer. JAMA, 2001, 285(3): 324-328.
22.	Ambrosini G, Adjda C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphma. Nat Med, 1997, 3(8): 917-921.
23.	Marx D, Binder C, Meden H, et al. Differential expression of apoptosis associated gene bax and bcl-2 in ovarian cancer. Anticancer Res, 1997, 17(3C): 2233-2240.

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55(2): 74-108.
2. Basu P, De P, Mandal S, et al. Study of pattern of care of ovarian cancer patients in specialized cancer institute in Kolkata, Eastern India. Indian J Cancer, 2009, 46(1): 28-33.
3. Modepalli N, Venugopal SB. Clinicopathological study of surface epithelial tumours of the ovary: an isntitutional study. J Clin Diagn Res, 2016, 10(10): EC01-EC04.
4. 李克红, 张若曦, 张英杰, 等. 凋亡抑制基因 Survivin 在卵巢癌组织中的表达及其临床意义. 中国实用医刊, 2012, 39(8): 4-6.
5. 史惠蓉, 兰莉, 乔玉环, 等. 卵巢癌组织中 Survivin 和 PCNA 的表达. 郑州大学学报(医学版), 2004, 39(4): 552-554.
6. 宋和存, 向征, 李慧. Survivin Ki67 在卵巢原发癌与转移癌中的表达及其临床意义. 中国实用妇科与产科杂志, 2006, 22(3): 201-203.
7. 王言奎, 杨锦芝, 罗兵, 等. 上皮性卵巢癌中 Survivin 的表达及意义. 中国妇产科临床杂志, 2003, 4(5): 368-372.
8. 杨锦芝, 赵冬梅. 凋亡抑制基因 Survivin 在上皮性卵巢癌中的表达及其意义. 滨州医学院学报, 2003, 26(4): 243-244.
9. Li GZ, Pei SL, Hong LM, et al. Survivin expression in ovarian cancer. Exp Oncol, 2007, 29(2): 121-125.
10. 张淑兰, 赵长清, 林蓓, 等. 凋亡抑制基因 survivin 在卵巢上皮性癌组织中的表达及其与 bcl-2、bax 蛋白表达的关系. 中华妇产科杂志, 2003, 38(4): 203-206.
11. 张树荣, 杨淑莉, 李荷莲. 卵巢癌组织中 MDR1、Survivin、TopoⅡβ 的表达及临床意义. 中国妇幼健康研究, 2006, 17(6): 464-466.
12. 张意茗, 张向宁. XIAP、survivin、LPA 及 CA125 在上皮性卵巢癌中的表达. 山东大学学报(医学版), 2007, 45(3): 317-321.
13. 赵杨, 张颐, 温放. 凋亡抑制蛋白和耐药因子在卵巢癌中的表达及与化疗的关系. 解剖科学进展, 2007, 13(2): 111-114, 118.
14. Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the qualityof nonrandomized studies in meta-analysis. Available at: .
15. 许英艺, 张雅雅, 卢伟锋, 等. 骨桥蛋白表达与中国人肝癌及临床病理特征关系的 Meta 分析. 中国循证医学杂志, 14(12): 1418-1423.
16. Ambrosini G, Adida C, Sirugo G, et al. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem, 1998, 273(18): 11177-11182.
17. Shin S, Sung BJ, Cho YS, et al. An anti-apoptotic protein human a survivin is a direct inhibitor of caspase-3 and -7. Biochemistry, 2001, 40(4): 1117-1123.
18. Grossman D, McNiff JM, Li F, et al. Expression and targeting of the apoptosis inhibtitor, Survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line. Lab Invest, 1999, 79(9): 1121-1126.
19. Grossman D, McNiff JM, Li F, et al. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol, 1999, 113(6): 1076-1081.
20. Nasu S, Yangihashi A, Izawa A, et al. Survivin mRNA expression in patients with breast cancer. Anticancer Res, 2002, 22(3): 1839-1843.
21. Smith SD, Wheeler MA, Plescia J, et al. Urine detection of survivin and diagnosis of bladder cancer. JAMA, 2001, 285(3): 324-328.
22. Ambrosini G, Adjda C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphma. Nat Med, 1997, 3(8): 917-921.
23. Marx D, Binder C, Meden H, et al. Differential expression of apoptosis associated gene bax and bcl-2 in ovarian cancer. Anticancer Res, 1997, 17(3C): 2233-2240.

Chinese Journal of Evidence-Based Medicine

The association between the expression of Survivin mRNA and ovarian cancer: a meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content